Collagen type I and III synthesis by Tenon's capsule fibroblasts in culture: individual patient characteristics and response to mitomycin C, 5-fluorouracil, and ascorbic acid.
OBJECTIVE
This study was performed to better understand the differences between patients in specific components of wound healing as it may pertain to glaucoma filtration surgery, including the use of antimetabolites.


METHODS
Human Tenon's capsule fibroblasts were obtained at the time of glaucoma filtering surgery and established in individual cell cultures from 35 glaucoma patients. The dose-response to 5-fluorouracil (5FU) and mitomycin C (MMC) was determined. The individual cell lines were exposed to the antimetabolites and ascorbic acid with measurement of collagen type I and III production by an ELISA-type dot blot assay. These results were then statistically compared to the individual patient characteristics including age, race, previous surgery and medications, and type of glaucoma.


RESULTS
5-FU had little effect on collagen type I and III production or protein synthesis. MMC had an inhibitory effect on collagen secretion and total protein synthesis with increasing concentration. Photomicrographs of the cells after each treatment condition revealed characteristic morphologic changes when compared to controls. There was a large range of collagen type I and III production with correlation between the amounts of each collagen type secreted in response to the antimetabolites. However, there was no correlation with accepted risk factors for filtration failure.


CONCLUSIONS
These antimetabolites act similarly on different cell lines in a nonspecific manner. The results suggest that the increased risk of filtration failure due to age, race, diagnosis, and previous conjunctival surgery is not due to differences in secretion of collagen types I and III by Tenon's capsule fibroblasts.
Gross
R L
RL
Cullen Eye Institute, Department of Ophthalmology, Baylor College of Medicine, Houston, Texas, USA.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000963:Antimetabolites / Q000494:pharmacology; D001205:Ascorbic Acid / Q000494:pharmacology*; D002478:Cells, Cultured; D002648:Child; D003094:Collagen / Q000096:biosynthesis*; D003228:Conjunctiva / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D004797:Enzyme-Linked Immunosorbent Assay; D005347:Fibroblasts / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D018463:Filtering Surgery; D005472:Fluorouracil / Q000494:pharmacology*; D005901:Glaucoma / Q000601:surgery; D006801:Humans; D007223:Infant; D008875:Middle Aged; D016685:Mitomycin / Q000494:pharmacology*; D012189:Retrospective Studies; D012590:Sclera / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D014945:Wound Healing / Q000187:drug effects / Q000502:physiology
D000963:Antimetabolites; D016685:Mitomycin; D003094:Collagen; D001205:Ascorbic Acid; D005472:Fluorouracil